Is it safe to use Abilify (aripiprazole) 10 mg during pregnancy?

Abilify (Aripiprazole) 10mg in Pregnancy

Aripiprazole 10mg can be continued during pregnancy when the benefits of treating the underlying psychiatric condition outweigh potential risks, as untreated severe mental illness poses significant dangers to both mother and fetus, and available human data do not show a clear increased risk of major birth defects. 1

Risk-Benefit Framework

The decision to continue aripiprazole during pregnancy must weigh two competing risks:

Risks of untreated psychiatric illness:

• Increased risk of relapse, hospitalization, and suicide in the mother
• Schizophrenia and bipolar disorder are associated with adverse perinatal outcomes including preterm birth
• Women who discontinued antidepressants/antipsychotics during pregnancy showed higher relapse rates 1

Risks of aripiprazole exposure:

• Available epidemiologic data from 9,258 pregnancies exposed to atypical antipsychotics show no overall increased risk for major birth defects 1
• A prospective registry study of 158 women with first-trimester aripiprazole exposure found an adjusted odds ratio of 1.35 (95% CI: 0.43-4.20) for major malformations—not statistically significant 2

Specific Pregnancy Considerations

Third Trimester Neonatal Effects: Neonates exposed to aripiprazole in the third trimester are at risk for extrapyramidal and/or withdrawal symptoms after delivery, including:

• Agitation, hypertonia, hypotonia, tremor
• Somnolence, respiratory distress, feeding disorders

These symptoms vary in severity—some neonates recover within hours without treatment, while others require prolonged hospitalization. Monitor all exposed neonates closely after delivery. 1

Pregnancy Complications: One retrospective study (N=26) found associations with:

• Pregnancy-induced hypertension
• Lower birth weight and shorter gestation
• Higher neonatal admission rates 3

However, aripiprazole was NOT associated with gestational diabetes, which is reassuring given its favorable metabolic profile 3, 4

Critical Postpartum Warning: Lactation Failure

A major concern with aripiprazole is its significant impact on lactation. Despite being "prolactin-sparing," recent evidence shows:

• 74% of women experienced complete lactation failure
• 11% had insufficient milk production
• Mean dose was 16.4 mg/day 5

This lactation issue must be discussed with patients during pregnancy planning and early pregnancy to allow informed decision-making about infant feeding plans. 5

Clinical Management Algorithm

Preconception/Early Pregnancy:

1. Document psychiatric diagnosis and severity
2. Discuss risks of untreated illness vs. medication exposure
3. Explicitly counsel about high risk of lactation failure (74% complete failure rate)
4. Register patient with National Pregnancy Registry for Atypical Antipsychotics: 1-866-961-2388 1
5. If stable and low-risk illness, consider trial discontinuation; if moderate-severe illness, continue medication

During Pregnancy:

• Continue aripiprazole at lowest effective dose (10mg is reasonable starting dose)
• Monitor for pregnancy-induced hypertension closely
• Ensure adequate weight gain and fetal growth monitoring
• Avoid dose escalation unless clinically necessary

Third Trimester:

• Prepare neonatal team for potential withdrawal/extrapyramidal symptoms
• Do NOT discontinue medication to avoid neonatal effects—this increases maternal relapse risk

Delivery and Postpartum:

• Continue therapeutic dose through delivery
• Monitor neonate for 48-72 hours minimum for withdrawal symptoms
• Implement alternative feeding plan given high lactation failure risk
• Monitor mother closely for postpartum relapse (high-risk period)

Common Pitfalls to Avoid

1. Do not discontinue aripiprazole in third trimester to prevent neonatal symptoms—maternal relapse risk is greater than neonatal risk
2. Do not assume breastfeeding will be successful—proactively plan for formula feeding given 74% lactation failure rate
3. Do not use higher doses than necessary—10mg is often sufficient and minimizes fetal exposure
4. Do not forget to register with pregnancy registry—this contributes to future safety knowledge

Evidence Quality Note

While no randomized controlled trials exist (ethically impossible), the available prospective registry data from over 9,000 pregnancies and specific aripiprazole data from 158 first-trimester exposures provide reasonable reassurance regarding major malformations 1, 2. The lactation data, though from smaller studies, is consistent and concerning 5.

The FDA label explicitly states that published epidemiologic studies "have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal outcomes." 1